Table 2.
Frequency distribution of clinical and tumor features for N = 99 cases
| Breast diagnosis | N (%) | Percent × 100 |
| CIS | 11 | 11 |
| DCIS-mINV | 15 | 15 |
| Invasive carcinoma | 73 | 73 |
| Tumor stage | ||
| TIS | 11 | 11 |
| T1 | 53 | 53 |
| T2 | 30 | 30 |
| T3 | 5 | 5 |
| Tumor grade | ||
| I | 10 | 10 |
| II | 71 | 70 |
| III | 15 | 15 |
| LCIS | 3 | 3 |
| Bilateral breast Dx | ||
| Yes | 19 | 19 |
| No | 80 | 80 |
| Metastatic disease | ||
| Yes | 17 | 17 |
| No | 82 | 82 |
| Recurrence | ||
| Yes | 24 | 24 |
| No | 75 | 75 |
| Age of cancer onset | ||
| <30 | 4 | 4 |
| 30–39 | 19 | 19 |
| 40–49 | 43 | 43 |
| 50–59 | 28 | 28 |
| 60–69 | 4 | 4 |
| 70–79 | 1 | 1 |
| Lymph node status | ||
| Positive | 27 | 27 |
| Negative | 72 | 72 |
| ER IHC status | ||
| Positive | 60 | 60 |
| Negative | 28 | 28 |
| ND | 11 | 11 |
| PR IHC status | ||
| Positive | 63 | 63 |
| Negative | 24 | 24 |
| ND | 12 | 12 |
| HER2 IHC status | ||
| Positive | 21 | 21 |
| Negative | 36 | 36 |
| ND | 42 | 42 |
| Deceased | ||
| Yes | 13 | 13 |
| No | 86 | 86 |
| BRCA mutation status | ||
| BRCA+ | 11 | 11 |
| UNK | 7 | 7 |
| VUS | 6 | 6 |
| NEG | 26 | 26 |
| NT | 49 | 49 |
Breast diagnosis: CIS, carcinoma in situ; DCIS-mINV, case diagnosed with a <1.0 cm micro-invasive carcinoma, but for which only DCIS remained on the tissue block; IC, invasive carcinoma. Lymph node status: indicates if lymph nodes were positive or negative for tumor cells at initial diagnosis of breast cancer. ER, PR and HER2 status: IHC tumor staining with antibodies to the estrogen and progesterone receptors, and HER2 growth factor receptor, respectively. BRCA mutation status: genetic mutation testing of BRCA1 and BRCA2 genes; BRCA+, carrier of a known deleterious BRCA1 or BRCA2 mutation; UNK, test results unknown. By report, the individual underwent BRCA mutation testing, but the test result was not reported in any of the three Johns Hopkins clinical databases abstracted in the study. VUS, variant of unknown significance; e.g., a BRCA gene mutation was found, but no population data as yet exists to determine if the mutation is deleterious; NEG, negative, the patient did not carry a BRCA1 or BRCA2 gene mutation. NT, not tested.